Skip to content

Novel Therapeutic Frontiers in Duchenne Muscular Dystrophy: Gene Therapy, Exon Skipping, and Stem Cell Approaches.

Sep 2026 · Current pharmaceutical design · 0 citations
Medicine

TL;DR

Through multidisciplinary treatment and continuous scientific progress, individualized precision medicine that integrates therapies targeting secondary pathogenic pathways with dystrophin-restoration techniques can finally convert this devastating illness into a tolerable chronic ailment.

Abstract

Duchenne Muscular Dystrophy (DMD) is a chronic X-linked recessive neuromuscular disorder with a prevalence of 1 in 3,500 to 5,000 live male births worldwide. Alterations in the dystrophin gene, one of the biggest known human genes with 2.5 million base pairs and 79 exons, located at Xp21.1, are responsible for the disease. The dystrophin protein, an essential structural component that links the muscle cell cytoskeleton actin to the extracellular matrix through the dystrophin-associated protein complex, is either lacking or dysfunctional due to these mutations. Dystrophin deficiency compromises muscle membrane stability, leading to gradual deterioration of muscle fibers, fibrosis, and replacement by adipose tissue. Numerous disrupted physiological pathways, such as calcium dysregulation, faulty nitric oxide signaling, altered PI3K-Akt-mTOR growth signaling, chronic inflammatory responses, and oxidative stress, are implicated in the pathophysiology of DMD. Affected males clinically demonstrate early childhood muscular weakness; characteristic signs such as Gower's maneuver and calf hypertrophy; increasing ambulation loss by adolescence; and potentially lethal cardiorespiratory problems that generally manifest in the third decade of life. Corticosteroids remain the primary therapeutic modality, significantly improving ambulation and quality of life; nevertheless, extended use entails severe adverse effects. Recent treatment advancements provide renewed optimism via diverse innovative strategies, namely CRISPR-Cas9 gene editing, antisense oligonucleotide-mediated exon skipping (eteplirsen, golodirsen, viltolarsen, and casimersen), microdystrophin gene therapy using Adeno-Associated Viral (AAV) vectors, stop codon read-through therapy, and stem cell-based treatments. But difficulties with cost, immunogenicity, efficacy, and mutant specificity persist. Through multidisciplinary treatment and continuous scientific progress, individualized precision medicine that integrates therapies targeting secondary pathogenic pathways with dystrophin-restoration techniques can finally convert this devastating illness into a tolerable chronic ailment.

View source

Similar papers

Review Open access Sep 2026

Duchenne Muscular Dystrophy: from Dystrophin Deficiency to Emerging Therapeutic Strategies

DMD is a severe, progressive X-linked recessive neuromuscular disorder caused by pathogenic mutations in the DMD gene, resulting in deficiency or absence of the dystrophin protein, and multidisciplinary management has improved survival and quality of life.

B. Rakesh, A. A, D. S. et al. · 0 citations
Open access Sep 2026

Mechanisms of Cardiac Cell Death in Duchenne Muscular Dystrophy

Results suggest that apoptotic and pyroptotic pathways are not active in these tissue samples, suggesting that alternative cell death pathways, such as necroptosis, may be responsible, or these animals had not undergone significant cardiomyocyte cell death.

Caroline Lee, Ryan W. Krueger, Brooke Harris et al. · 0 citations
#gene editing Sep 2026

Development of an AAV-Encoded Adenine Base Editor for Duchenne Muscular Dystrophy.

It is suggested that even modest levels of base editing-mediated exon skipping may ameliorate the DMD cardiac phenotype toward a BMD-like state, supporting the translational potential of this dual rAAV base editing approach for DMD cardiomyopathy.

Ina Luksch, Christine M. Poch, Aylin Mayer et al. · 0 citations

Advancing adeno-associated virus (AAV) gene therapy for Duchenne muscular dystrophy

A human skeletal muscle xenograft model is adapted, using 222 transplanted muscles from human donors, to use as a platform for AAV delivery and shows for the first time, that human muscles transplanted in immune-deficient mice are efficiently transduced by AAV vectors at following intravenous injection of the host mice...

Matthew J Burke · 0 citations
Review Open access Aug 2026

Characterization of Dystrophin-Related Syndromes: Carriers, DMD, and BMD

Primary dystrophin deficiency, caused by X-chromosome mutations within the DMD gene, encompasses a continuous clinical spectrum of neurological, muscular, and cardiac disorders known as dystrophinopathies that exhibit profound phenotypic variability driven by specific mutation profiles and epigenetic factors. This comp...

N. Chabbi, Corrado Angelini, I. García et al. · 0 citations

Related blog posts

Microsoft Research Blog Nov 12, 2026

Microsoft Research Focus – Edition #98

What's new in research at Microsoft? Host Anson Ho explores the latest, including AI-powered universal translation, a breakthrough in a 31-year-old mathematics challenge, and advances making AI coding agents faster and more efficient.  The post Microsoft Research Focus – Edition #98 appeared first on Microsoft Research.

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.